Antisense Therapeutics Ltd
ASX:ANP
Net Margin
Antisense Therapeutics Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| AU |
|
Antisense Therapeutics Ltd
ASX:ANP
|
75.7m AUD |
-2 956%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
770.2B USD |
23%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
404.9B USD |
25%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
2T DKK |
35%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
206.2B CHF |
14%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
179.7B CHF |
25%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
167.5B GBP |
14%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
213.1B USD |
27%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
183.8B USD |
-126%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
140.9B USD |
13%
|
Antisense Therapeutics Ltd
Glance View
Antisense Therapeutics Ltd. engages in the research and development of novel antisense pharmacceuticals. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-12-20. The firm is engaged in developing and commercializing antisense pharmaceuticals for unmet markets in rare diseases. The firm's product candidate, ATL1103, is an antisense drug designed to block growth hormone receptor (GHr) expression thereby reducing levels of the hormone insulin-like growth factor-I (IGF-I) in the blood. ATL1103 is in clinical development for acromegaly. The firm's product candidate, ATL1102, is an antisense inhibitor targeting very late antigen 4 (VLA-4), an immune cell molecule. The firm completed a Phase IIa efficacy and safety trial of ATL1102 in multiple sclerosis (MS) patients. The firm is engaged in clinical development of ATL1102 in patients with Duchenne Muscular Dystrophy (DMD). The firm is conducting a Phase II clinical trial of ATL1102 in DMD patients.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Antisense Therapeutics Ltd's most recent financial statements, the company has Net Margin of -2 956.4%.
You don't have any saved screeners yet